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A B S T R A C T   
Introduction: Adults with Down syndrome are genetically predisposed to develop Alzheimer’s disease and 
accumulate beta-amyloid plaques (Aβ) early in life. While Aβ has been heavily studied in Down syndrome, its 
relationship with neurofibrillary tau is less understood. The aim of this study was to evaluate neurofibrillary tau 
deposition in individuals with Down syndrome with varying levels of Aβ burden. 
Methods: A total of 161 adults with Down syndrome (mean age = 39.2 (8.50) years) and 40 healthy, non-Down 
syndrome sibling controls (43.2 (12.6) years) underwent T1w-MRI, [C-11]PiB and [F-18]AV-1451 PET scans. 
PET images were converted to units of standardized uptake value ratios (SUVrs). Aβ burden was calculated using 
the amyloid load metric (AβL); a measure of global Aβ burden that improves quantification from SUVrs by 
suppressing the nonspecific binding signal component and computing the specific Aβ signal from all Aβ-carrying 
voxels from the image. Regional tau was assessed using control-standardized AV-1451 SUVr. Control- 
standardized SUVrs were compared across Down syndrome groups of Aβ-negative (A-) (AβL < 13.3), sub-
threshold A+ (13.3 ≤ AβL < 20) and conventionally A+ (AβL ≥ 20) individuals. The subthreshold A + group was 
identified as having significantly higher Aβ burden compared to the A- group, but not high enough to satisfy a 
conventional A + classification. 
Results: A large-sized association that survived adjustment for chronological age, mental age (assessed using the 
Peabody Picture Vocabulary Test), and imaging site was observed between AβL and AV-1451 within each Braak 
region (p < .05). The A + group showed significantly higher AV-1451 retention across all Braak regions 
compared to the A- and subthreshold A + groups (p < .05). The subthreshold A + group showed significantly 
higher AV-1451 retention in Braak regions I-III compared to an age-matched sample from the A- group (p < .05). 
Discussion: These results show that even the earliest detectable Aβ accumulation in Down syndrome is accom-
panied by elevated tau in the early Braak stage regions. This early detection of tau can help characterize the tau 
accumulation phase during preclinical Alzheimer’s disease progression in Down syndrome and suggests that 
there may be a relatively narrow window after Aβ accumulation begins to prevent the downstream cascade of 
events that leads to Alzheimer’s disease.  
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1. Introduction 
Adults with Down syndrome are at high risk of developing Alz-
heimer’s disease. Down syndrome is characterized by triplication of 
chromosome 21, which encodes production of the amyloid precursor 
protein (APP) and results in early amyloid-β (Aβ) plaque deposition in 
the brain (Oyama et al., 1994; Rumble et al., 1989). There is a sharp 
increase in prevalence of Alzheimer’s disease dementia after age 50 in 
Down syndrome (Schupf, 2002), with the average age of dementia onset 
at 55 years (Strydom et al., 2018). The lifetime risk of developing Alz-
heimer’s disease in Down syndrome is over 90% (McCarron et al., 2017, 
2014), with a survival time of ~4 years following a dementia diagnosis 
(Sinai et al., 2018). Since Alzheimer’s disease is the leading cause of 
death in this population (Hithersay et al., 2019), there is motivation to 
include individuals with Down syndrome in trials aimed at Alzheimer’s 
disease treatment and prevention, and particularly anti-amyloid 
interventions. 
The progression of Aβ plaques throughout Alzheimer’s disease in 
Down syndrome has been studied extensively. Pittsburgh Compound-B 
(2-(4′-[11C]methylaminophenyl)-6-hydroxybenzothiazole, [C-11]PiB) 
is a positron emission tomography (PET) radiotracer that is used for 
the non-invasive imaging of Aβ plaques in neuronal tissue. Using [C-11] 
PiB PET, the earliest region of prominent Aβ retention was identified as 
the striatum (Handen et al., 2012). This striatum-first pattern of Aβ 
deposition in Down syndrome is consistent with the observations in 
individuals with autosomal-dominant Alzheimer’s disease and APP 
duplication (Bateman et al., 2012; Klunk et al., 2007; Remes et al., 2008; 
Villemagne et al., 2009). Similar to late-onset Alzheimer’s disease, 
Down syndrome presents identical patterns of cortical Aβ retention 
(Annus et al., 2016; Cole et al., 2017; Hartley et al., 2014; Jennings et al., 
2015; Landt et al., 2011; Lao et al., 2018, 2016; Mak et al., 2019; 
Matthews et al., 2016; Rafii et al., 2015, 2017; Sabbagh et al., 2015) and 
shows longitudinal increases of ~3–4% per year, however with a wide 
variation in the age of Aβ onset (Lao et al., 2017; Tudorascu et al., 2019; 
Zammit et al., 2020). In late-onset Alzheimer’s disease, striatal Aβ 
retention is observed much later in the disease progression (Hanseeuw 
et al., 2018) compared to Down syndrome, indicating that the striatum 
can be used as an early marker of Alzheimer’s disease progression in this 
population (Cohen et al., 2018). The onset of brain amyloidosis in Down 
syndrome occurs some 10 to 15 years earlier than in the non-Down 
syndrome general population and the deposition of amyloid plaques is 
necessary but not sufficient for onset of cognitive symptoms. 
With improvements in PET quantification techniques, emphasis has 
been placed on early detection of Aβ, specifically at subthreshold 
detection levels where the total Aβ burden would not satisfy a conven-
tional Aβ-positive (A+) classification. In late-onset Alzheimer’s disease 
studies, subthreshold Aβ change has been linked to early tau change and 
worsening cognitive performance (Hanseeuw et al., 2019; Landau et al., 
2018; Leal et al., 2018). To better characterize subthreshold Aβ change 
in Down syndrome, our previous work evaluated longitudinal Aβ accu-
mulation during the earliest stages of Aβ accumulation. Aβ accumulation 
in individuals with Down syndrome at typical subthreshold levels was 
found to be similar to Aβ accumulation in individuals with Down syn-
drome with moderate to high Aβ burden. Using the longitudinal Aβ data, 
a cutoff representing subthreshold A+ was established to distinguish 
early Aβ accumulators from Aβ-negative (A− ) non-accumulators given 
just a single PET scan (Zammit et al., 2021). The classification of sub-
threshold A+ was leveraged using longitudinal evaluation with the 
amyloid load metric (AβL). The AβL metric is similar to Centiloids and at 
the cross-sectional level both measures are highly correlated, but AβL 
shows improved longitudinal stability due to its suppression of the 
nonspecific binding signal component of PET images (Whittington and 
Gunn, 2018). Because of this, abnormal increases in Aβ for A- in-
dividuals can be measured more accurately, allowing for the determi-
nation of a subthreshold A+ cutoff (Zammit et al., 2021). In addition, 
AβL obtains information from all Aβ-carrying voxels in the brain rather 
than from a select number of ROIs, providing an estimate of the true 
global Aβ burden. 
The progression of neurofibrillary tau accumulation and its rela-
tionship to Aβ and cognitive decline has been of recent interest. The 
emergence of tau PET radiotracers, such as flortaucipir (7-(6-(18F)flu-
oropyridin-3-yl)-5H-pyrido[4,3-b]indole, [F-18]AV-1451) (Xia et al., 
2013), allows for an in vivo measurement of the degree and spatial extent 
of tau deposition. Early tau PET studies in late-onset Alzheimer’s disease 
have shown that the spatial progression of PET-detectable tau tracks 
closely with the sequence of progression of tau pathology described in 
the classic studies of Braak and Braak (Lowe et al., 2018; Braak and 
Braak, 1997), that tau is highly associated with Aβ deposition and 
cognitive decline (Brier et al., 2016), and that tau PET can distinguish 
different clinical groups in the Alzheimer’s disease continuum (Johnson 
et al., 2016). In late-onset Alzheimer’s disease, tau PET has been shown 
to be more closely associated than Aβ PET with cognitive decline and 
dementia status (Ossenkoppele et al., 2016). However, these studies 
primarily focus on evaluation of individuals with high tau burden where 
cognitive decline is already present. Less emphasis has been placed on 
the detection of tau in early stage, presymptomatic disease where 
intervention may be more effective at preventing cognitive decline and 
neurodegeneration. 
While tau PET has rapidly been adapted for use in late-onset Alz-
heimer’s disease research studies, its use in Down syndrome has been 
understudied. Tau PET investigations in Down syndrome have demon-
strated that increased tau burden is very highly correlated with cogni-
tive impairment (Rafii et al., 2017) and that tau deposition in Braak 
stage regions III-VI accelerates with increasing Aβ deposition (Tudor-
ascu et al., 2020). A recent study in Down syndrome has shown elevated 
levels of phospho-tau in cerebrospinal fluid in the fourth decade of life, 
directly following increases in Aβ PET (Fortea et al., 2020). Similar to 
late-onset Alzheimer’s disease studies, evaluation of tau in Down syn-
drome has primarily focused on individuals with high Aβ and tau 
burden, with little emphasis on early tau detection. To date, no PET 
studies in Down syndrome have focused on detection of early tau in 
relation to early Aβ progression. 
The Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) 
is an ongoing longitudinal study with a large cohort aimed at charac-
terizing the progression of Alzheimer’s disease-related biomarker 
change in individuals with Down syndrome (Handen et al., 2020). The 
objectives of the current study were to assess neurofibrillary tau burden 
using AV-1451 PET and to compare Braak regional tau deposition to 
global Aβ. Using groups of A− , subthreshold A+ and conventionally A+
individuals with Down syndrome, regional AV-1451 was assessed to 
identify the earliest detectable increases in neurofibrillary tau. In an 
effort to identify and characterize the earliest detectable changes in PET- 
measured neurofibrillary tau and the relationship with Aβ, this investi-
gation will expand upon the previous findings from ABC-DS by focusing 
on the deposition of neurofibrillary tau in individuals with very low 
levels of Aβ burden. 
2. Materials and Methods 
2.1. Participants 
The current sample included 161 adults with Down syndrome (mean 
age (SD) = 39.2 (8.50) years) recruited by the University of Wisconsin- 
Madison, University of Pittsburgh, University of Cambridge, and Barrow 
Neurological Institute sites of the ABC-DS study (Handen et al., 2020). 
Institutional Review Board approval and informed consent were ob-
tained during enrollment into the study by the participant or legally 
designated caregiver according to the Declaration of Helsinki. Inclusion 
criteria involved being aged ≥ 25 years and having a receptive language 
mental age of at least three years, based upon the Peabody Picture Vo-
cabulary Test Fourth Edition (PPVT) (Dunn and Dunn, 2007). Genetic 
testing was performed to confirm Down syndrome (trisomy 21, 
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mosaicism, or partial translocation). Exclusion criteria included having 
an unstable psychiatric condition (e.g. untreated) that impaired cogni-
tive functioning or a medical condition that was contraindicative of 
brain imaging scans (e.g. metallic implants). In the current study, eight 
participants were classified having Alzheimer’s disease, eight were 
classified having mild cognitive impairment, 137 were cognitively sta-
ble, and the remaining eight showed cognitive decline but possibly due 
to non-Alzheimer’s disease reasons (e.g., life stressors or medical con-
ditions). Determination of cognitively stable status was based on 
consensus process that involved review of caregiver-reported and 
directly-administered measures of cognition and adaptive behavior and 
was made in consideration of premorbid intellectual disability level, 
psychiatric and medical conditions and major life events (Hartley et al., 
2020). These diagnostic classifications were performed independent of 
imaging findings and based on case consensus processing informed by 
directly administered and caregiver-reported measures as previously 
described (Handen et al., 2020). Participant demographics are outlined 
in Table 1. 
Additionally, 40 sibling controls (43.2 (12.6) years) without Down 
syndrome were enrolled in the study to act as a biomarker reference 
group. The control group was age-matched to the participants with 
Down syndrome and were determined to be free of symptoms of de-
mentia based on the Montreal Cognitive Assessment (Nasreddine et al., 
2005) and the Eight-Item Interview to Differentiate Aging and Dementia 
(Galvin et al., 2005, 2006). The control group underwent the same im-
aging protocols as the participants with Down syndrome but were not 
administered any additional cognitive testing or neurological 
examinations. 
2.2. Sociodemographics 
Chronological age was coded in years and sex was coded as M/F as 
reported by caregivers. The Peabody Picture Vocabulary Test – Fourth 
Edition (PPVT) (Dunn and Dunn, 2007) was administered to assess 
lifetime cognitive ability. The PPVT has been shown to be a valid 
measure of receptive language in adults with Down syndrome that 
highly correlates with IQ (Phillips et al., 2014). 
2.3. Imaging 
T1-weighted magnetic resonance imaging (MRI) scans were acquired 
on a GE Discovery MR750 (Wisconsin), Siemens Trio or Prisma (Pitts-
burgh), GE SIGNA (Cambridge), and GE Discovery MR750 (Barrow). 
MRI images were processed using FreeSurfer v5.3.0 for region of interest 
(ROI) definition. Positron emission tomography (PET) scans were per-
formed on a Siemens ECAT HR + scanner (Wisconsin/Pittsburgh), 
Siemens 4-ring Biograph mCT (Pittsburgh), GE SIGNA (Cambridge), and 
GE Discovery 710 (Barrow). A target dose of 15 mCi of [C-11]Pittsburgh 
Compound-B (PiB) was injected intravenously, and PET scans were used 
to measure Aβ acquired 50–70 min post-injection (four 5-minute 
frames). Following completion of the PiB scan, a target dose of 10 mCi 
of [F-18]AV-1451 was injected intravenously, and PET scans were used 
to measure neurofibrillary tau acquired 80–100 min post-injection (four 
5-minute frames). Using the Statistical Parametric Mapping 12 software 
(SPM12), PET frames were re-aligned to correct for motion and averaged 
to form a 3D image. 
2.4. Aβ PET quantification 
PiB PET images were spatially normalized to the Montreal Neuro-
logical Institute 152 space (MNI152) via a Down syndrome-specific PET 
template for PiB as previously described (Lao et al., 2018). For all im-
ages, spatial normalization was required to calculate the amyloid load 
(AβL) (Whittington and Gunn, 2018); a global measure of Aβ burden 
calculated from the linear least squares method between the PET image 
and images of specific and nonspecific PiB binding defined in MNI152 
space. Standardized uptake value ratio (SUVr) images were generated by 
voxel normalization to cerebellar gray matter, and the global AβL was 
calculated following methodology specific to Down syndrome PiB im-
ages as previously described (Zammit et al., 2020). Because the striatum 
is a region of interest in the monitoring of early Alzheimer’s disease 
progression in Down syndrome, striatal PiB SUVr was also calculated for 
each participant. Participants were classified as Aβ-negative (A-) for AβL 
< 13.3 (Centiloid < 18.0), subthreshold A+ for 13.3 ≤ AβL < 20 (18.0 ≤
Centiloid < 33.3), and conventionally A+ for AβL ≥ 20 (Centiloid ≥
33.3). The conventional A+ cutoff was derived in Down syndrome by 
linearly transforming a previously established SUVr/Centiloid cutoff for 
A+ into units of AβL (Zammit et al., 2020). The cutoff for subthreshold 
A+ was derived from a longitudinal analysis that distinguished early Aβ 
accumulators from non-accumulators prior to surpassing the conven-
tional A+ cutoff (Zammit et al., 2021). The conversion from AβL to 
Centiloids is as follows: 
Centiloid = 2.27*AβL − 12.1 (1) 
Because these two metrics are very highly correlated at the cross- 
sectional level, an individual’s group assignment would not change if 
Centiloids were used for classification instead of AβL. 
2.5. Tau PET quantification 
AV-1451 PET images were coregistered to the T1w-MRI for the Down 
syndrome and sibling control participants. SUVr images were generated 
by voxel normalization to cerebellar gray matter and regional SUVrs 
were extracted from Braak regions I-VI (Schöll et al., 2016), with the 
exception that the striatum was not included in Braak region V. No 
erosion or elimination of regions of focal uptake of AV-1451 was per-
formed on the cerebellar gray matter ROI used for signal normalization. 
Briefly, the T1w-MRI were processed using FreeSurfer v5.3.0 to delin-
eate anatomical ROI masks for multiple brain regions. ROI masks from 
FreeSurfer were combined to create Braak stage ROIs, which were used 
to calculate the average AV-1451 SUVr within each Braak region. SUVr 
images were partial volume corrected using the geometric transfer 
matrix (GTM) method (Rousset et al., 1998), which has shown to be an 
effective method of reducing spillover effects from the choroid plexus in 
AV-1451 images (Baker et al., 2017). Quantification from non-PVC SUVr 
images was used for Braak regions III-VI, but due to AV-1451 off-target 
binding concerns in the choroid plexus, quantification from GTM-PVC 
results was used for Braak regions I-II. The mean SUVr values and 
standard deviations were calculated for each Braak region in the sibling 
control group and were used to compute a “control-standardized SUVr” 
score for the participants with Down syndrome. The control- 
standardized SUVr is a type of Z-score, but instead of being standard-
ized to the mean and the distribution of the Down syndrome population, 
it is standardized to the mean and the distribution of the sibling control 
population. This provides the advantage of interpreting these derived 
scores in terms of how low/high the Down syndrome group is relative to 
the sibling controls. The T1w-MRI were then spatially normalized to the 
MNI152 space using SPM12, and the resulting deformation fields were 
Table 1 
Down syndrome participant demographics categorized by Aβ status.   
All A- Subthreshold 
A+
A+
Number of participants 161 108 22 31 
Sex (M/F) 81/80 52/56 11/11 18/13 




44.4 (6.32) 50.4 
(4.70) 




10.0 (3.07) 8.49 
(3.23) 
Mild cognitive impairment/ 
Alzheimer’s disease 
consensus 
16 1 1 14  
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used to spatially normalize the AV-1451 SUVr images. 
2.6. Statistical analyses 
All statistical analyses were performed using SAS 9.4. Global AβL and 
Braak regional AV-1451 control-standardized SUVrs were compared 
using Pearson’s partial correlations while adjusting for age, PPVT, and 
imaging site. For Braak regions I-II, the Pearson’s partial correlations 
were also adjusted for AV-1451 in the choroid plexus. The Pearson’s 
analysis was then repeated to compare striatal PiB SUVr to Braak 
regional control-standardized SUVr. AV-1451 control-standardized 
SUVrs across all Braak regions were then compared across groups of A-, 
subthreshold A+, and A+ individuals with Down syndrome using 
analysis of covariance (ANCOVA) while adjusting for age, PPVT and 
imaging site. For Braak regions I-II, the ANCOVA analysis also included 
AV-1451 in the choroid plexus as a covariate. Individual group com-
parisons were then performed by taking the least square differences 
between the means while adjusting for multiple comparisons using the 
Tukey-Kramer method. Group-averaged AV-1451 images (MNI152 
space) were then generated for the A- and subthreshold A+ groups, and 
the difference was taken between the images to visualize regional dif-
ferences in AV-1451 retention. Because the mean age of the subthresh-
old A+ group was ~10 years older than the A- group, an additional 
analysis was performed with an age-matched sample of the A- and 
subthreshold A+ groups to account for age-related effects. Using an age- 
matched sample of A- and subthreshold A+ Down syndrome, Braak 
regional AV-1451 control-standardized SUVrs were compared using 
two-tailed Student’s t-tests while adjusting for imaging site. For Braak 
regions I-II, all comparisons were made both with and without GTM 
correction. 
2.7. Data availability 
The imaging sites have entered web-based data through the Alz-
heimer’s Therapeutic Research Institute (ATRI) as part of the ABC-DS 
study. Data from the ABC-DS study and research methodology is 
currently available to the scientific community through the LONI 
database. 
3. Results 
3.1. Global AβL, striatal PiB SUVr and Braak regional AV-1451 
In this cohort, 108 individuals with Down syndrome were classified 
as A-, 22 were subthreshold A+, and 31 were conventionally A+. 
Representative AV-1451 SUVr images showing elevated binding in each 
Braak region are displayed in Fig. 1. Average AV-1451 SUVr images for 
the A-, subthreshold A+ and conventionally A+ groups are displayed in 
Fig. 2. Fig. 3 displays the AV-1451 control-standardized SUVr with 
respect to global AβL for each individual Braak region. Pearson’s partial 
correlations (presented as Pearson’s R [95% CI]) revealed significant 
positive associations (all p < .0001) with a large magnitude effect size 
(Cohen’s d) (Cohen, 1988, 1992) between AβL and AV-1451 in all Braak 
regions (Braak I: 0.70 [0.61, 0.77]; Braak II: 0.74 [0.66, 0.81]; Braak III: 
0.83 [0.77, 0.87]; Braak IV: 0.79 [0.72, 0.84]; Braak V: 0.81 [0.75, 
0.86]; Braak VI: 0.77 [0.70, 0.83]). Following GTM correction, signifi-
cant associations between AβL and AV-1451 remained significant in 
Braak regions I (0.56 [0.44, 0.66]) and II (0.56 [0.44, 0.66]). Pearson’s 
partial correlations were then performed between striatal PiB SUVr and 
Braak regional AV-1451. Positive associations were observed between 
striatal PiB and AV-1451 in all Braak regions (Braak I: 0.65 [0.55, 0.74]; 
Braak II: 0.66 [0.56, 0.74]; Braak III: 0.63 [0.52, 0.72]; Braak IV: 0.58 
[0.46, 0.68]; Braak V: 0.58 [0.46, 0.68]; Braak VI: 0.51 [0.38, 0.62]). 
Following GTM correction, significant associations between striatal PiB 
and AV-1451 remained significant in Braak regions I (0.55 [0.42, 0.66]) 
and II (0.50 [0.37, 0.61]). All associations survived adjustment for age, 
PPVT, and imaging site. In addition, the associations for Braak regions I- 
II survived adjustment for AV-1451 in the choroid plexus. 
3.2. AV-1451 retention relative to Aβ status 
From ANCOVA, significant differences in AV-1451 control-stan-
dardized SUVr were observed between the A-, subthreshold A+, and A+
groups for Braak regions I (F(df) = 23.4(6), p < .0001), II (F(df) = 40.4 
(6), p < .0001), III (F(df) = 32.8(5), p < .0001), IV (F(df) = 22.7(5), p <
.0001), V (F(df) = 17.9(5), p < .0001), and VI (F(df) = 10.6(5), p <
.0001). Additionally, significant differences were observed following 
Fig. 1. Representative AV-1451 images for individuals with Down syndrome across each Braak stage, and for the sibling controls.  
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GTM correction in Braak regions I (F(df) = 14.8(6), p < .0001) and II (F 
(df) = 24.7(6), p < .0001). All associations survived adjustment for age, 
PPVT and imaging site. The associations for Braak regions I-II also sur-
vived adjustment for AV-1451 in the choroid plexus. From the individ-
ual group comparisons, least square differences between the means 
(with 95% CIs) for all Braak regions are displayed in Table 2. The A+
group showed significantly higher AV-1451 control-standardized SUVrs 
relative to the A- and the subthreshold A+ groups across Braak regions I- 
VI (all p < .0001 adjusted for multiple comparisons). The subthreshold 
A+ group showed significantly higher AV-1451 control-standardized 
SUVrs compared to the A- group in Braak regions I (adjusted p = .0021) 
and II (adjusted p = .0031) without GTM correction, and in Braak re-
gions I (adjusted p < .0001) and II (adjusted p = .0001) with GTM 
correction. The subthreshold A+ group did not differ from the A- group 
in Braak regions III-VI (all p > .05 adjusted for multiple comparisons). 
3.3. Age-matched comparison between AV-1451 retention for A- and 
subthreshold A+ groups 
The SUVr difference image between the subthreshold A+ group- 
averaged and A- group-averaged AV-1451 images revealed higher 
retention in Braak regions I-III for the subthreshold A+ group (Fig. 4). 
Similarly, the SUVr difference image for age-matched samples of these 
groups revealed the same pattern of higher AV-1451 retention in Braak 
regions I-III in the subthreshold A+ group (Fig. 4). Using an age- 
matched sample of A- (n = 72) and subthreshold A+ (n = 22) in-
dividuals with Down syndrome, a Student’s t-test analysis was per-
formed to compare Braak regional AV-1451 retention between groups. 
AV-1451 control-standardized SUVrs were significantly higher in 
Braak regions I-III (all p < .05) for the subthreshold A+ group, and no 
significant difference was observed in Braak regions IV-VI between 
groups (Table 3). Imaging site did not influence the model outcome. 
3.4. Discussion 
Due to the similarities in Alzheimer’s disease biomarker progression 
between Down syndrome and late-onset Alzheimer’s disease, Down 
syndrome can serve as a model population for trials aimed at Alz-
heimer’s disease prevention, such as those involving anti-amyloid 
treatments. Since the Down syndrome population is uniformly affected 
by Alzheimer’s disease pathology during the fourth decade of life and 
progression of Alzheimer’s disease biomarkers follow a predictable time 
course, recruitment of these individuals into projects such as the Trial- 
Ready Cohort – Down Syndrome (TRC-DS) study (Rafii et al., 2020) is 
more feasible compared to those at risk for late-onset Alzheimer’s dis-
ease development. Our previous work in this population evaluated the 
longitudinal spread of Aβ (Zammit et al., 2021, 2020; Lao et al., 2017; 
Tudorascu et al., 2019), neurofibrillary tau deposition (Tudorascu et al., 
2020), glucose hypometabolism (Lao et al., 2018; Zammit et al., 2020) 
and cognitive decline (Hartley et al., 2020) in order to characterize these 
biomarkers within the amyloid/tau/neurodegeneration (AT(N)) frame-
work of Alzheimer’s disease (Jack et al., 2016; Rafii et al., 2020). The 
current work builds upon these previous findings by evaluating neuro-
fibrillary tau deposition during the earliest stages of Aβ accumulation in 
order to better characterize early tau progression. With a better char-
acterization of early tau in relation to Aβ, clinical trial studies can utilize 
tau PET to evaluate whether an anti-amyloid therapy is effective at 
preventing tau progression, especially that tau is more strongly corre-
lated with cognitive decline. 
Using AV-1451 PET, we have shown that Braak regional tau in Down 
syndrome is highly associated with global Aβ burden measured using 
AβL. The greatest associations between Aβ and tau were observed in 
Braak regions III-VI. In the A+ group, AV-1451 retention appeared to 
plateau with increased Aβ in Braak regions I-II, whereas Braak regions 
III-VI showed significantly increased tau burden. The lack of significant 
tau increase with Aβ in these early Braak regions is not unique to Down 
syndrome, as Braak I-II tau also appears to plateau while cortical regions 
continue to escalate in late-onset Alzheimer’s disease (Jack et al., 2019; 
Schwarz et al., 2016). This may indicate that the associations between 
Aβ and tau in these early Braak regions are primarily driven by in-
dividuals with low to moderate Aβ burden, and that the positive asso-
ciation between biomarkers diminishes with higher Aβ levels. In a study 
of autosomal dominant Alzheimer’s disease, striatal PiB showed greater 
associations with tau compared to cortical PiB (Hanseeuw et al., 2019), 
and it is suggested that striatal PiB may also be highly associated with 
regional tau spread in Down syndrome. To evaluate this, Pearson’s 
partial correlations were performed between striatal PiB SUVr and Braak 
regional AV-1451 in our Down syndrome cohort. Striatal PiB SUVr was 
highly associated with Braak regional tau, however, the effect sizes were 
not as large when compared to global AβL. The large effect sizes 
observed with AβL are likely a result of the improved sensitivity this 
metric provides to detect Aβ when compared to SUVr. Our previous 
work in Down syndrome reported significant associations between 
increased Aβ burden and cognition as well as associations between 
glucose hypometabolism and cognition (Zammit et al., 2020), and work 
is currently ongoing to evaluate the association of tau (treated as a 
continuous variable) across a range of cognitive domains. 
While tau in Braak regions I-II had significant associations with Aβ, 
Fig. 2. Average AV-1451 SUVr images for groups of A-, subthreshold A+ and conventionally A+ individuals with Down syndrome.  
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the quantification of tau in these regions was likely influenced by signal 
spillover from off-target AV-1451 binding in the choroid plexus (Lois 
et al., 2019). To account for choroid plexus spillover, the geometric 
transfer matrix (GTM) method of partial volume correction was per-
formed on Braak regions I-II. Following GTM correction, the associations 
between Aβ and tau remained significant in these regions. Due to off- 
target binding of AV-1451 in the basal ganglia, the striatum was 
excluded from Braak region V in these analyses. The voxel analysis 
evaluating SUVr difference images between subthreshold A+ and A−
groups did reveal elevated striatal AV-1451 retention in the subthresh-
old A+ group, but when compared to an age-matched sample of A- in-
dividuals with Down syndrome, no difference was observed between 
striatal retention. This finding indicates that the striatal AV-1451 
binding observed in Down syndrome may be age-related, similar to 
the patterns of increased AV-1451 retention in healthy controls with age 
(Smith et al., 2017). An AV-1451 study in frontotemporal dementia 
evaluated the potential of W-score maps (a modified Z-score adjusted for 
covariates) relative to a healthy control group to monitor increased 
retention while correcting for age-related effects (Tsai et al., 2019). Due 
to the association between age and off-target AV-1451 binding in the 
striatum, this methodology may be useful to distinguish Alzheimer’s 
disease-related increases in striatal AV-1451 retention in Down syn-
drome. Because the striatum is a region of early Aβ deposition in Down 
syndrome, evaluation of the striatum with a radiotracer free from off- 
Fig. 3. Braak regional AV-1451 control-standardized SUVr with respect to global AβL for A-, subthreshold A+, and A+ Down syndrome.  
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target basal ganglia binding may better characterize tau spread in this 
region. Our findings also suggest that the spatial patterns of tau follow 
the conventional Braak staging of tau pathology, as elevated tau was not 
present within a late Braak region at the individual level without already 
being elevated in each antecedent region. These findings are in accor-
dance with our previous findings in Down syndrome showing that 
higher tau pathology emerges in Braak stage regions as Aβ pathology 
increases, and that the associations between Aβ and tau are similar to 
late-onset Alzheimer’s disease (Tudorascu et al., 2020). 
When evaluating Braak regional tau across groups based on Aβ sta-
tus, the conventionally A+ group had significantly higher tau burden in 
all Braak regions compared to the subthreshold A+ and A− groups. 
Compared to the A- group, the subthreshold A+ group had significantly 
higher tau deposition in Braak regions I-II. Because the mean age of the 
subthreshold A+ group was ~10 years older than the A- group, an 
additional analysis was performed using an age-matched sample from 
the A- group to account for age-related effects. Given the age-matched 
samples, tau burden in Braak regions I-III was significantly higher in 
the subthreshold A+ group compared to the A- group, suggesting that Aβ 
status rather than age is a better indicator of tau presence. These findings 
suggest that tau deposition in Down syndrome can be detected during 
the subthreshold Aβ accumulation phase, highlighting the importance of 
early detection and intervention of Alzheimer’s disease biomarker pro-
gression. The identification of early tau with subthreshold Aβ accumu-
lation is not unique to Down syndrome, as both elevated tau and 
worsening cognitive performance were accompanied by subthreshold 
Aβ in late-onset Alzheimer’s disease (Hanseeuw et al., 2019). Another 
study in late-onset Alzheimer’s disease reports that individuals with 
subthreshold Aβ had predictable neocortical tau spread within a 5 year 
period, followed shortly by cognitive decline (Leal et al., 2018). 
Furthermore, memory decline was observed with subthreshold Aβ 
accumulation in healthy, older adults at risk for Alzheimer’s disease 
(Landau et al., 2018). Due to the similarities between Alzheimer’s dis-
ease pathology progression in Down syndrome and late-onset Alz-
heimer’s disease, individuals with Down syndrome with a subthreshold 
A+ classification should be more carefully evaluated for cognitive 
decline. 
For this analysis, we chose to quantify tau using control-standardized 
SUVrs from the AV-1451 data relative to the sibling control group. 
Control-standardized SUVrs were used as this method standardizes the 
SUVr by accounting for the regional variance of AV-1451 binding 
(Vemuri et al., 2017). Because the control-standardized SUVr is a 
method of Z-transforming the AV-1451 data, the associations observed 
between groups in this study would be the same as those observed with 
non-standardized SUVr. There are benefits to using control-standardized 
SUVrs, as this method can facilitate head-to-head comparisons of im-
aging studies that utilize different populations and different tau radio-
tracers, and they can also be used to generate a standardized cutoff for 
tau-positivity (T+) that would theoretically be similar across all tau 
PET radiotracers (Villemagne et al., 2020). For the current study, 
control-standardized SUVrs provided the sensitivity to identify very 
early tau deposition during the subthreshold Aβ accumulation phase, 
and lay the groundwork for establishing a T+ cutoff for Down syndrome 
within the AT(N) classification scheme (Jack et al., 2016; Rafii et al., 
2020). 
Future work in this population will focus on further evaluation of Aβ, 
tau, and neurodegeneration throughout Alzheimer’s disease progres-
sion. Additionally, cutoffs for T+ in Down syndrome will be explored 
and can be validated (Salvadó et al., 2019) against plasma or cerebro-
spinal fluid biomarkers of total tau and phospho-tau181 (Handen et al., 
2020) or phospho-tau217 (Mattsson-Carlgren, et al., 2021) that have 
been collected as part of ABC-DS. Longitudinal imaging of tau is also 
needed to explore tau accumulation across the different stages of Alz-
heimer’s disease progression. Comparisons of tau with changes in 
cognition will also be performed using established outcome measures of 
cognitive decline for Down syndrome (Hartley et al., 2020). 
3.5. Conclusion 
Evaluating PiB and AV-1451 PET in a large Down syndrome popu-
lation revealed significant associations between Aβ deposition and 
Braak-regional tau deposition. The A+ Down syndrome group showed 
higher tau burden in Braak regions I-VI compared to the subthreshold 
A+ and A− Down syndrome groups. The subthreshold A+ group showed 
significantly higher tau burden in Braak regions I-III compared to an age- 
matched subset of the A− group, suggesting that tau deposition begins 
very early in the preclinical Alzheimer’s disease phase. 
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